Presents: The Value of Streamlined Coverage for Real-Time CGM to Optimize Outcomes and Resource Utilization for Members with Diabetes


Monica Peek, MD, MPH, MS
Professor of Medicine
Associate Director
Chicago Center for Diabetes Translational Research
The University of Chicago Medicine
Click here for biography

Samir Mistry, PharmD, MBA
Vice President of Pharmacy Strategy & Services
Capital Blue Cross
Click here for biography

Kelly Close
Founder, The diaTribe Foundation
President, Close Concerns
Click here for biography

Target Audience

This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.

Statement of Need/Program Overview

The true impact of diabetes-related severe hypoglycemia (SH) events is often underestimated by payers, with only approximately 5% of self-reported events among pharmacologically treated patients being captured by health care utilization-based surveillance. Racial/ethnic minority populations and other members affected by SDOH experience further worsening outcomes and resource utilization resulting from type 2 diabetes (T2D), necessitating specialized engagement and intervention. Continuous glucose monitoring (CGM) represents a significant advancement in the precision management of T2D, providing members with the ability to receive a virtually uninterrupted stream of information about the current physiology of their disease. However, many providers cite that prior authorizations delay treatment and negatively impact clinical outcomes. A smart edit featuring an automated look back in claims data for a previous insulin prescription can be used as the criterion for approval with real-time adjudication, easing the administrative burden for payers and providers and streamlining access for members. This approach serves as a basic blueprint for payers to apply the latest evidence in advancing T2D management with optimal outcomes and cost reduction.

Educational Objectives 
After completing this activity, the participant should be better able to:

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Impact Education, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit
Medical Education Resources designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.0 contact hour.

Pharmacist Credit

Medical Education Resources (MER) designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.

Universal Program Number – JA0003680-9999-22-012-H01-P
This activity is certified as Knowledge-based CPE.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosure of Conflicts of Interest
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Name of Faculty Reported Financial Relationship

Monica Peek, MD, MPH

No financial interest/relationships relating to the topic of this activity.

Samir Mistry, PharmD, MBA

No financial interest/relationships relating to the topic of this activity.

Kelly Close

No financial interest/relationships relating to the topic of this activity.

The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Name of Content Manager Reported Financial Relationship

MER Content Managers

No financial relationships to disclose.

Impact Education, LLC Staff

No financial relationships to disclose.

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Impact Education, LLC, and/or Dexcom, Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

There are no fees for participating and receiving CME/CE credit for this activity. During the period July 15, 2022, through January 31, 2024, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the activity evaluation form, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.


There is no fee for this educational activity.